American Association for Cancer Research
10559965epi090359-sup-0359_sup_table_1.pdf (23.47 kB)

Supplementary Table 1 from Gene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers

Download (23.47 kB)
journal contribution
posted on 2023-03-31, 14:01 authored by Yoland C. Antill, Gillian Mitchell, Sandra A. Johnson, Lisa Devereux, Alvin Milner, Juliana Di Iulio, Geoffrey J. Lindeman, Judy Kirk, Kelly Anne Phillips, Ian G. Campbell
Supplementary Table 1 from Gene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers



Purpose: Genomic alterations (including gene hypermethylation) are likely to precede the phenotypic changes associated with breast tumorigenesis. From a prospective collection of ductal lavage (DL) samples from women with a known mutation in BRCA1 or BRCA2, we have assessed promoter methylation with a comparison of results with several variables, including breast cancer (BC) outcome.Experimental Design: Hypermethylation of p16, RASSF1A, twist, and RARβ was assessed using a qualitative, real-time, nested PCR assay. Associations between methylation status and variables were tested using Fisher's exact test or logistic regression. Analyses were done at three levels: a single breast, a single duct (both over time), and each DL sample in isolation.Results: A total of 168 samples from 93 ducts in 54 breasts have been analyzed in 34 women (16 BRCA1 and 18 BRCA2 mutation carriers). A median of 2 DL was done (range, 1–5), with 7 women developing BC on study, 1 bilateral. Methylation of p16 was associated with a known BRCA1 mutation (P = 0.001, P < 0.001, and P < 0.001 for breast, duct, and sample levels, respectively) and women with a history of contralateral BC (P = 0.001 and P < 0.001 for duct and sample levels, respectively). An association was seen for women who developed BC on study and RASSF1A methylation (P = 0.001 for sample level).Conclusions: Genetic methylation patterns could potentially be used to predict future BC risk. In addition, p16 methylation may be a predictor of BRCA1 mutation status. Further research is required to corroborate these findings. Cancer Epidemiol Biomarkers Prev; 19(1); 265–74